Treatment of BPH with kushmandbeejtaila

A Clinicocomparative study on kushmandbeej taila uttarbasti and matrabasti in the management of Mootraghata w.s.r. to Benign Prostatic Hyperplasia.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/04/008423

Enrollment

Registered

2017-04-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Benign Prostatic Hyperplasia

Interventions

Intervention1: Kushmand beej tail uttarbasti: 25 Patients will be given Uttarbasti with Kushmandbeej taila. 36 uttarbasti in 4 cycles for duration of 21 days with gap of 3 days between each cycle. Con

Eligibility

Inclusion criteria

Inclusion criteria: Patients presenting with classical signs & symptoms of BPH. Patients of any cast, religion. Controlled case of Diabetes mellitus and Hypertension. Prostate size (volume) up to 50 cc in USG KUB. post void residual volume upto 100 cc

Exclusion criteria

Exclusion criteria: Patients with malignancy. Prostate size (volume) more than 50cc in USG. post void residual volume more than 100cc. Patients with systemic diseases like Tuberculosis, HIV, HBsAg, Uncontrolled DM and HTN. Patients with coagulopathy like Haemophilia and Von Will brandâ??s disease. Vulnerable group of people like mentally ill.

Design outcomes

Primary

Measure	Time frame
symptomatic relief, prostate size reduction and post void volume reduction.Timepoint: after 21 days from treatment started.	—

Secondary

Measure	Time frame
safety from other complications.Timepoint: after 4 months of treatment started	—

Countries

India

Contacts

Public ContactDr Harshit Shah

Govt.Akhandanand Ayurved Mahavidyalaya, GAU

drshilpavinay@gmail.com08511082205

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026